Navigation Links
Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
Date:3/31/2009

SYDNEY, March 31 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced completion of the first component of its Phase III international trial assessing the effectiveness of Bronchitol in people with cystic fibrosis.

The final subject has now completed their final clinical visit and the trial has run to time and budget. The first subject entered the trial in April 2007.

The trial was conducted in 40 centres in four different countries and involved 325 randomized subjects with cystic fibrosis. The trial was a double blind, placebo controlled study designed with the assistance of the European regulatory agency (EMEA) and with the objective of seeking a marketing approval for Bronchitol for treating cystic fibrosis in Europe and elsewhere.

The results of the trial are expected to be available later this month after data review and statistical analysis of the various endpoints have been completed. The first objective of the trial is to demonstrate an improvement in lung function. Consistent loss of lung function is the leading cause of death of people with cystic fibrosis.

Dr Alan Robertson, Pharmaxis Chief Executive Officer said: "We are very pleased to announce this major milestone for Pharmaxis and look forward to the results of the study with great interest. It is hoped Bronchitol will change the therapeutic landscape for people living with cystic fibrosis and provide a new therapeutic regimen that helps to prolong life."

The second component of the trial will examine the safety of Bronchitol in people with cystic fibrosis.

Pharmaxis has received Orphan Drug Designation and fast track status from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency for Bronc
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
2. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Pharmaxis Establishes Named Patient Program for Bronchitol
5. Pharmaxis Long-Term Safety Study of Bronchitol Completes
6. Schering-Plough Announces Results of the Early ACS Trial
7. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
8. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
9. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
10. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ – Small Cap IR issues ... to supply custom Arrayit blood card technology to Vivos, ... on earth. Vivos offers an impervious, impenetrable and permanent ... woman and child on Earth, a safe and secure ... blood cards allow the rapid collection, separation, drying and ...
(Date:6/30/2015)... 30, 2015  Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and ... results from a Category 3 human abuse ... extended-release, oral oxycodone product candidate in late-stage ... severe enough to require daily, around-the-clock opioid ...
(Date:6/30/2015)... 30, 2015 PharmaVentures is pleased ... Chip-Man Technologies Oy (CMT) on its divestment of certain ... to CMTs world leading capabilities in cellular imaging and ... a series of successful global deals in the life ... Fintan Walton , CEO, PharmaVentures, commented: "PharmaVentures is ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector 2
... SAN DIEGO, May 5, 2011 /PRNewswire/ -- Halozyme ... developing and commercializing products targeting the extracellular matrix , ... of America Merrill Lynch Health Care Conference in Las Vegas. ... PDT (2:10 p.m. EDT). To listen to the live webcast ...
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... 31, 2011.  Savient ended the quarter with $268.0 million in ... December 31, 2010, primarily due to the issuance and sale ... the first quarter of 2011, the Company had a net ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 7
(Date:7/1/2015)... ... 2015 , ... Nutritional Products International, a brand focused on the global marketing ... 2015 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida, where it made ... trade show allows companies the chance to meet with a variety of the most ...
(Date:7/1/2015)... ... , ... Recent research has revealed that most adults lack confidence in the ... professionals. Starting the last Monday of June, Whiter Image Dental will help ... on the customer’s first popular In-Office 2 Patient Kit. , The ...
(Date:7/1/2015)... ... July 01, 2015 , ... Effective June 9, 2015, the Radiology Business ... The annual board election process has been in place since the RBMA was founded ... Suzanne Taylor, BS, FRBMA, succeeds Keith E. Chew, MHA, CMPE, as president. Ms. Taylor ...
(Date:6/30/2015)... ... ... In the Spring of 2015, as California imposed unprecedented water-use restrictions on its cities ... first time since records have been kept, the New York Times reported that “the ... drought.” , In response to the potentially devastating effects of these current ...
(Date:6/30/2015)... PA (PRWEB) , ... June 30, 2015 , ... America ... by cardiovascular disease, cancer, autism, dementia, auto-immune deficiencies, or obesity. Why? , The answer ... , Dr. Pete Sulack, America’s Leading Stress Expert, has successfully treated over one million ...
Breaking Medicine News(10 mins):Health News:NPI Meets With Top Retail Figures at ECRM Conference 2Health News:Whiter Image Dental Offers New Customers Half-Off Teeth Whitening Kit 2Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 2Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 3Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 4Health News:RainSoil launches water-retention product as drought spreads. 2Health News:RainSoil launches water-retention product as drought spreads. 3Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2
... 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) today ... will provide a corporate,overview at the upcoming Collins Stewart ... July 8, 2008 in New York, NY., Interested ... visiting,the Sunesis website at http://ir.sunesis.com . A replay ...
... Rigel Pharmaceuticals,Inc. (Nasdaq: RIGL ) today announced that ... will present a company overview,at the Fourth Annual Collins ... a.m. EDT at The Mandarin Oriental Hotel in New ... or the subsequent archived recording,log on to http://www.rigel.com ...
... 2 The Michigan Attorney General announced,on July 2 ... Shield of,Michigan challenging a capital transaction between BCBSM and ... position that BCBSM is not,authorized by Public Act 350 ... Accident Fund obtained prior regulatory approval for the,transaction. BCBSM ...
... has spread to distant sites has a poor prognosis, but ... slow disease progression in some patients, a research team led ... Cancer Center reports in the July 3rd edition of ... drug, motesanib diphosphate, is a VEGF inhibitor, a biologic agent ...
... 2 A Miami resident was,sentenced to 130 months ... the,Medicare program, Acting Assistant Attorney General Matthew Friedrich of,the ... the Southern,District of Florida announced today., Gustavo Smith, ... for,the Southern District of Florida by Judge Marcia G. ...
... Hanger Orthopedic,Group, Inc. (NYSE: HGR ) ... Services revised its outlook for Hanger Orthopedic Group, ... corporate credit,rating at "B." "The outlook revision reflects ... improved financial risk profile," said,Standard & Poor,s credit ...
Cached Medicine News:Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 2Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
Wolfs unique apron and vest set distributes weight evenly between shoulders and hips. The vest comes with an attached Thyroid collar...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
Medicine Products: